|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
AU4746590A
(en)
|
1988-12-28 |
1990-08-01 |
Stefan Miltenyi |
Methods and materials for high gradient magnetic separation of biological materials
|
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
CA2410510A1
(en)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Artificial antigen presenting cells and methods of use thereof
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
WO2002050071A1
(en)
|
2000-12-21 |
2002-06-27 |
Bristol-Myers Squibb Company |
Thiazolyl inhibitors of tec family tyrosine kinases
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
SE0202463D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel compounds
|
|
SE0202429D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel Compounds
|
|
SE0202461D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel compounds
|
|
SE0202462D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel use
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
PT1682553E
(pt)
|
2003-09-08 |
2010-07-29 |
Aventis Pharma Inc |
Tienopirazoles
|
|
US20050176792A1
(en)
|
2004-01-14 |
2005-08-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Ketone substituted benzimidazole compounds
|
|
WO2005079791A1
(en)
|
2004-02-12 |
2005-09-01 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
|
|
US8101770B2
(en)
|
2004-12-16 |
2012-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyridones useful as inhibitors of kinases
|
|
WO2007016977A1
(de)
|
2005-08-05 |
2007-02-15 |
Delica Ag |
Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel
|
|
WO2007027594A1
(en)
|
2005-08-29 |
2007-03-08 |
Vertex Pharmaceuticals Incorporated |
3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
|
|
EP1957491A2
(en)
|
2005-11-12 |
2008-08-20 |
Boehringer Ingelheim International GmbH |
Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
|
|
US20080293714A1
(en)
|
2005-12-20 |
2008-11-27 |
Joerg Martin Bentzien |
Tec Kinase Inhibitors
|
|
EP2027087A2
(en)
|
2006-05-18 |
2009-02-25 |
MannKind Corporation |
Intracellular kinase inhibitors
|
|
EP1900727A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Aminopyridine derivatives as kinase inhibitors
|
|
EP1900739A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Diazolodiazine derivatives as kinase inhibitors
|
|
JP5336375B2
(ja)
|
2006-08-30 |
2013-11-06 |
セルゾーム リミテッド |
キナーゼ阻害剤としてのトリアゾール誘導体
|
|
EP2526933B1
(en)
|
2006-09-22 |
2015-02-25 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
WO2008121420A1
(en)
|
2007-03-30 |
2008-10-09 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
AU2008314632B2
(en)
|
2007-10-19 |
2015-05-28 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
ES2640216T3
(es)
|
2007-12-07 |
2017-11-02 |
Miltenyi Biotec Gmbh |
Sistemas y métodos para procesamiento de células
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
EP3549934A1
(en)
|
2008-06-27 |
2019-10-09 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
WO2011017219A1
(en)
|
2009-08-03 |
2011-02-10 |
The Regents Of The University Of California |
Imidazoquinoxalinones and anti-tumor treatment
|
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
|
|
CA3154024C
(en)
|
2010-06-03 |
2024-02-27 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
|
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
|
ES2841983T3
(es)
|
2011-03-23 |
2021-07-12 |
Hutchinson Fred Cancer Res |
Método y composiciones para inmunoterapia celular
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
BR112014011417B1
(pt)
|
2011-11-11 |
2021-10-13 |
Fred Hutchinson Cancer Research Center |
Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
KR20150009556A
(ko)
|
2012-05-03 |
2015-01-26 |
프레드 헛친슨 켄서 리서치 센터 |
증강된 친화성 t 세포 수용체 및 이의 제조 방법
|
|
US9296753B2
(en)
|
2012-06-04 |
2016-03-29 |
Pharmacyclics Llc |
Crystalline forms of a Bruton's tyrosine kinase inhibitor
|
|
WO2014004707A1
(en)
|
2012-06-29 |
2014-01-03 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
WO2014031687A1
(en)
|
2012-08-20 |
2014-02-27 |
Jensen, Michael |
Method and compositions for cellular immunotherapy
|
|
CN112430580A
(zh)
|
2012-10-02 |
2021-03-02 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
|
TW201427664A
(zh)
|
2012-11-02 |
2014-07-16 |
Pharmacyclics Inc |
Ｔｅｃ家族激酶抑制劑佐劑療法
|
|
WO2014082085A1
(en)
|
2012-11-26 |
2014-05-30 |
The University Of North Carolina At Chapel Hill |
Use of itk inhibitors for the treatment of cancer
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
CN104781789B
(zh)
|
2012-12-20 |
2018-06-05 |
三菱电机株式会社 |
车载装置
|
|
US9499519B2
(en)
|
2012-12-26 |
2016-11-22 |
Medivation Technologies, Inc. |
Fused pyrimidine compounds and use thereof
|
|
KR20160006668A
(ko)
|
2013-03-14 |
2016-01-19 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물
|
|
US9550760B2
(en)
|
2013-03-15 |
2017-01-24 |
Nantbioscience, Inc. |
Substituted indol-5-ol derivatives and their therapeutic applications
|
|
CA2908375A1
(en)
|
2013-04-08 |
2014-10-16 |
Pharmacyclics Llc |
Ibrutinib combination therapy
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
|
SG10201804439PA
(en)
|
2013-12-20 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
|
WO2015127261A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
|
AU2015237744A1
(en)
|
2014-03-27 |
2016-09-15 |
Wavelength Enterprises Ltd |
Ibrutinib solid forms and production process therefor
|
|
WO2015187848A1
(en)
|
2014-06-04 |
2015-12-10 |
Sampath Deepa |
Hdac inhibitor and btk inhibitor combinations
|
|
WO2015192081A1
(en)
|
2014-06-13 |
2015-12-17 |
Byrd, John C. |
Biomarker for predicting response of cll to treatment with a btk inhibitor
|
|
CA2954652A1
(en)
|
2014-07-11 |
2016-01-14 |
Celgene Corporation |
Combination therapy for cancer
|
|
WO2016014859A1
(en)
|
2014-07-25 |
2016-01-28 |
Pharmacyclics Llc |
Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
|
|
WO2016022942A1
(en)
|
2014-08-07 |
2016-02-11 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
|
AU2015300966A1
(en)
|
2014-08-08 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Bruton's tyrosine kinase inhibitor combinations and uses thereof
|
|
EP3180343A1
(en)
|
2014-08-14 |
2017-06-21 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
ES2727952T3
(es)
|
2014-10-01 |
2019-10-21 |
Ratiopharm Gmbh |
Sal de adición de ácido de ibrutinib
|
|
WO2016088074A1
(en)
|
2014-12-03 |
2016-06-09 |
Dr. Reddy’S Laboratories Limited |
Process for the preparation of amorphous ibrutinib
|
|
MX2017008486A
(es)
|
2014-12-23 |
2017-09-19 |
Pharmacyclics Llc |
Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
|
|
MA41350A
(fr)
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
|
SG11201707122QA
(en)
|
2015-03-03 |
2017-09-28 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
|
WO2016139588A1
(en)
|
2015-03-03 |
2016-09-09 |
Dr. Reddy's Laboratories Limited |
Polymorphs of ibrutinib
|
|
WO2016151438A1
(en)
|
2015-03-20 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of ibrutinib
|
|
EP3277688B1
(en)
|
2015-04-02 |
2019-05-08 |
ratiopharm GmbH |
Co-crystals of ibrutinib
|
|
CN108135904A
(zh)
|
2015-08-31 |
2018-06-08 |
药品循环有限责任公司 |
用于治疗多发性骨髓瘤的btk抑制剂组合
|
|
ITUB20155616A1
(it)
|
2015-11-16 |
2017-05-16 |
Laboratorio Chimico Int S P A |
Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina.
|
|
WO2017134684A2
(en)
|
2016-02-01 |
2017-08-10 |
Natco Pharma Limited |
An improved process for the preparation of ibrutinib
|
|
WO2017134588A1
(en)
|
2016-02-04 |
2017-08-10 |
Shilpa Medicare Limited |
Process for the preparation of ibrutinib
|
|
GB2558514A
(en)
|
2016-02-09 |
2018-07-18 |
Azad Pharmaceutical Ingredients Ag |
Process for the synthesis of stable amorphous ibrutinib
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
IL299099A
(en)
|
2016-06-27 |
2023-02-01 |
Univ California |
Combinations of cancer treatments
|